The Debate over Combination Drug Policy for Malaria: It May Not Just Be the Patients' Temperatures Which Need to Be Brought Down

Attaran A Barnes KI Curtis C . WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 2004; 363: 237–40.

Mutabingwa T Nzila A Mberu E . Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 2001; 358: 1218–23.

World Health Organization. Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation [document WHO/CDS/RBM/2001.35]. Geneva: WHO, 2001.

Whitty CJM Allan R Wiseman V . Averting a malaria disaster in Africa - where does the buck stop?. Bull World Health Organ 2004; 82: 381–4.

Dorsey G Njama D Kamya MR . Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 2002; 360: 2031–8.

Adjuik M Agnamey P Babiker A . Amodiaquineartesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002; 359: 1365–72.

Staedke SG Kamya MR Dorsey G . Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 2001; 358: 368–74.

McGready R Cho T Keo NK . Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis 2001; 33: 2009–16.

World Health Organization. Assessment of the Safety of Artemisinin Compounds in Pregnancy. Geneva: WHO, 2003.